According to billionaire entrepreneur Elon Musk, human trials for a wireless device produced by his brain chip company Neuralink are anticipated to start in six months. Neuralink is working on brain chip interfaces that, according to the company, will help people with disabilities move and communicate. Neuralink has been testing its products on animals while […]

According to billionaire entrepreneur Elon Musk, human trials for a wireless device produced by his brain chip company Neuralink are anticipated to start in six months. Neuralink is working on brain chip interfaces that, according to the company, will help people with disabilities move and communicate. Neuralink has been testing its products on animals while […]

Washington [US], May 6 (ANI): The US Food and Drug Administration (FDA) on Thursday said that the Johnson & Johnson vaccine that has been administered to more than 18 million Americans can potentially cause "life-threatening blood clots", and thereby warranted "limiting the authorized use of the vaccine."

A patient’s failing heart was replaced with the heart of a genetically engineered pig, known as the process of xenotransplantation, in a groundbreaking operation at the University of Maryland Medical Centre in Baltimore, United States. But he died two months later on Tuesday (March 8). On January 10, the successful transplantation procedure was in news, […]

New Delhi Feb 19 PTI Bharat Biotech on Saturday said its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US In a statement Ocugen Inc Bharat Biotechs partner in the US and Canada for Covaxin noted that the American health regulator -- the US Food and Drug Administration FDA -- has lifted its clinical hold to evaluate the COVID-19 vaccine candidate BBV152 known as Covaxin outside the US Covaxin BBVI52 which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research ICMR is an investigational vaccine candidate product in the US Ocugen Inc is co-developing the Covaxin vaccine candidate for COVID-19 in the US and Canada We are pleased to be able to move our clinical program for Covaxin forward which we hope will bring us closer to offering an alternative COVID-19 vaccine Ocugen CEO and co-founder Shankar Musunuri said in a statement He further said We firmly believe that managing this pandemic requires more than one approach to vaccines so we are heartened to be able to continue developing our vaccine candidate With more than 200 million doses having been administered to adults outside the US Covaxin is currently authorised under emergency use in 20 countries Applications for emergency use authorisation are pending in more than 60 other countries The World Health Organisation WHO recently added Covaxin to its list of vaccines authorised for emergency use As many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using Covaxin In a separate statement on Twitter Bharat Biotech noted that Covaxin is the only vaccine in India to have published clinical data for children 2-18 years of age while trashing few media reports which questioned the efficacy of the jab These trials were conducted based on regulatory approvals by the CDSCO and DCGI it said The vaccine was evaluated in 175 subjects in the 12-18 years age group and 350 subjects in children below 12 years of age it added It was one of the few vaccines to be evaluated in children with published data Overall Covaxin has more than 15 publications elucidating all aspects of the safety immunogenicity efficacy and effectiveness in adults and children This level of data transparency demonstrates a high degree of confidence in the product the company stated Every batch of Covaxin requires more than 250 quality control tests before it can be released for supplies it added The vaccine has been administered in more than 300 million subjects globally Bharat Biotech stated Since the start of the childrens vaccination program on January 3 2022 70 per cent of the children in the 15-18 years age group have received the first dose and more than 25 per cent of the children in the 15-18 years age group have also received their second doses it said Over 7 crore doses have been administered to children since January 2022 it added PTI MSS ABM ABM

Hyderabad (Telangana) [India], February 19 (ANI): Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States.

New York [US], February 2 (ANI): The pharmaceutical companies, Pfizer and BioNTech, are seeking Emergency Use Authorization for their COVID-19 vaccine for use in children between six months and four years of age.

Washington [US], December 31 (ANI): As the US continues to register a record number of COVID-19 cases, American tennis legend Jimmy Connors has called on the Biden government and country's regulatory authority to recognise India's indigenously developed coronavirus vaccine COVAXIN for its vaccination programme.

.Washington [US], December 23 (ANI): The US Food and Drug Administration (FDA) on Wednesday (local time) authorized Pfizer's Paxlovid COVID-19 pill for high-risk people aged 12 and over to treat coronavirus disease (COVID-19).

Washington [US], November 18 (ANI): Biden administration on Thursday (local time) announced that they have purchased 10 million treatment courses of Pfizer's antiviral COVID-19 pill.